Hepatocurative effect of emblica officinalis against CYP 450 bio-activation hepatotoxicity of drugs

A method of treating CYP 450 and free radical mediated hepatotoxicity caused by at least one anti-TB drug selected from the group consisting of rifampicin, pyrazinamide, and isoniazid so as to restore liver function to normal, comprising:

• (a) providing an orally-administered composition comprising an extract from Emblica officinalis and pharmaceutically acceptable additives, said extract comprising from 8.5% to 15% by weight of tannin, said extract and said additives being in the ratio of 1:1–1:10, the additives being selected from a group of nutrients comprising proteins, carbohydrates, sugar, talc, magnesium stearate, cellulose, calcium carbonate, starch-gelatin paste, and/or pharmaceutically acceptable carrier, excipient, diluent, or solvent, wherein said composition treats CYP 450 bio-activated hepatotoxicity induced by at least one anti-TB drug selected from the group consisting of rifampicin, pyrazinamide, and isoniazid so as to restore liver function to normal, but is not effective against hepatotoxicity which is independent of bio-activation by CYP 450
• (b) introducing drug toxicity in hepatocytes of said subject,
• (c) orally administering a hepatocurative dosage of said composition to a subject having said hepatocytes exposed to drug hepatotoxicity, and
• (d) measuring changes in the level of liver/serum markers to estimate hepatocurative effect of the said composition.